Sept. 15, 2004 — The U.S. Food and Drug Administration (FDA) approved in June revisions to safety labeling to advise healthcare professionals of the following changes: adalimumab has been associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results